Emiliano Calvo, Victoria Bolós, Enrique Grande

). Read article or submit your manuscript for publishing."/>
skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Multiple roles and therapeutic implications of Akt signaling in cancer

Review

(4242) Views  (1173) Full article downloads

Authors:

Emiliano Calvo, Victoria Bolós, Enrique Grande

Published Date June 2009 Volume 2009:2 Pages 135 - 150
DOI: http://dx.doi.org/10.2147/OTT.S4943

Emiliano Calvo1, Victoria Bolós2, Enrique Grande2

1Centro Integral Oncológico Clara Campal (CiOCC), Madrid. Spain; 2Pfizer Oncology, Alcobendas-Madrid, Spain

Abstract: The prominence of the PI3K-Akt signaling pathway in several tumors indicates a relationship with tumor grade and proliferation. Critical cellular processes are driven through this pathway. More detailed knowledge of the pathogenesis of tumors would enable us to design targeted drugs to block both membrane tyrosine kinase receptors and the intracellular kinases involved in the transmission of the signal. The newly approved molecular inhibitors sunitinib (an inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and other tyrosine kinase receptors), sorafenib (a serine–threonine kinase inhibitor that acts against B-Raf) and temsirolimus (an mTOR inhibitor) shown clinical activity in advanced kidney cancer. Chronic myeloid leukemia has changed its natural history thanks to imatinib and dasatinib, both of which inhibit the intracellular bcr/abl protein derived from the alteration in the Philadelphia chromosome. Intracellular pathways are still important in cancer development and their blockade directly affects outcome. Cross-talk has been observed but is not well understood. Vertical and horizontal pathway blockade are promising anticancer strategies. Indeed, preclinical and early clinical data suggest that combining superficial and intracellular blocking agents can synergize and leverage single-agent activity. The implication of the Akt signaling pathway in cancer is well established and has led to the development of new anticancer agents that block its activation.

Keywords: Akt, cancer, therapeutic target, Akt inhibitors






 

Other articles by Dr Victoria Bolos



Readers of this article also read:

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer
Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Bendamustine in the treatment of non-Hodgkin’s lymphomas
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?